Weidemann Sören, Noori Nessar Ahmad, Lennartz Maximilian, Reiswich Viktor, Dum David, Menz Anne, Chirico Viktoria, Hube-Magg Claudia, Fraune Christoph, Bawahab Ahmed Abdulwahab, Bernreuther Christian, Simon Ronald, Clauditz Till S, Sauter Guido, Hinsch Andrea, Kind Simon, Jacobsen Frank, Steurer Stefan, Minner Sarah, Burandt Eike, Marx Andreas H, Krech Till, Lebok Patrick, Büscheck Franziska, Höflmayer Doris
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Department of Pathology, Faculty of Medicine, University of Jeddah, Jeddah 23890, Saudi Arabia.
Biomedicines. 2022 Oct 7;10(10):2507. doi: 10.3390/biomedicines10102507.
As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.
由于抑制素α（INHA）在相应的正常细胞类型中表达，它被用作肾上腺皮质肿瘤以及睾丸或卵巢性索间质肿瘤的免疫组织化学标志物。然而，其他肿瘤也可表达INHA。为全面确定INHA在癌症中的表达情况，通过免疫组织化学分析了一个包含来自134种不同肿瘤类型和亚型的15012个样本的组织微阵列。在134种肿瘤类别中有72种发现INHA呈阳性，其中26种类别有≥1例强阳性病例。在37例卵巢颗粒细胞瘤、43例卵巢/睾丸其他性索间质肿瘤、31例颗粒细胞瘤、28例腺瘤中的78.5%、25例肾上腺皮质癌中的44%以及15例胰腺腺泡细胞癌中的46.7%中发现INHA呈中度至强阳性。在另外46种肿瘤实体的病例中，<33%的病例至少有弱阳性的INHA表达。总之，这些数据支持使用INHA抗体来检测性索间质肿瘤、颗粒细胞瘤和肾上腺皮质肿瘤。由于在其他肿瘤实体中也可发现INHA，INHA免疫组织化学仅应被视为区分肿瘤实体的任何检测组合的一部分。
